US › Healthcare

Pacific Biosciences of California (PACB)

US · Healthcare · Medical Devices

$1.38+2.99%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

$39.0M

Revenue YoY

-1.9%

Net profit

$-44.7M

EPS

$-0.14

EPS estimate

$-0.14

Net margin

-114.7%

EPS came in at -0.14 against a street estimate of -0.14 — a beat of 0.0%.

Key statistics

Market cap

$404.1M

Forward P/E

0.0

P/B

170.66

Book value

$-0.11

EPS (TTM)

$-0.43

52-week high

$2.73

52-week low

$1.07

50-day MA

$1.38

200-day MA

$1.63

Beta

2.31

Analyst view

Analysts rate Pacific Biosciences of California a buy (6 buy, 8 hold, 0 sell out of 14) with an average price target of $2.16.

Shareholding

Insiders

8.91%

Institutions

55.47%

Largest institutional holders

Fund	Stake
ARK Investment Management LLC	11.67%
BlackRock Inc	8.13%
SoftBank Group Corp	6.58%
Vanguard Capital Management, LLC	4.11%
Amova Asset Management Americas, Inc	2.26%
Geode Capital Management, LLC	2.24%
State Street Corp	1.97%
Sumitomo Mitsui Trust Group Inc	1.93%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Pacific Biosciences of California — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.